A powerful alliance combining BioSkryb’s single-cell amplification chemistry with our OncoIncytes platform to unlock unprecedented insights into cancer biology and accelerate drug discovery.
A New Frontier in Single-Cell Research
We are thrilled to announce a landmark strategic partnership with BioSkryb Genomics – a pioneer in single-cell multi-omics technology to co-develop and commercialize next-generation single-cell multi-omic solutions that will fundamentally change how researchers and clinicians understand cancer at the molecular level.
This collaboration brings together two powerful and complementary technologies: BioSkryb’s patented Primary Template Amplification (PTA) chemistry- the foundation of their ResolveDNA®, ResolveOME®, and BaseJumper® bioinformatics solutions with our OncoIncytes platform and breakthrough CTC isolation capabilities. Together, we are creating an integrated solution that sets a new benchmark in precision, scale, and depth for single-cell analysis.
What This Partnership Unlocks
At the core of this alliance is the ability to isolate and analyze Circulating Tumor Cells at a ratio of 1 in a billion and then characterize their DNA, RNA, and surface proteins at the single-cell level with unprecedented accuracy. This integrated workflow opens transformative possibilities across cancer research, drug development, and precision medicine, including:
Accelerating the development of Antibody-Drug Conjugates (ADCs) by detecting protein expression on cell surfaces that no other liquid biopsy test can identify.
- Enabling real-time, longitudinal tracking of tumor evolution and treatment resistance
- Shortening drug development timelines and enhancing therapeutic precision
- Advancing biomarker discovery and patient stratification for clinical trials
Samples will be analyzed across two state-of-the-art laboratories: our CLIA-certified facility in Foster City, California, and BioSkryb’s services laboratory in Durham, North Carolina, giving researchers and clinicians access to comprehensive, high-resolution analytical capabilities.
What Our Partners Are Saying
“This collaboration represents a powerful synergy of visionary science and cutting-edge technologies,” said Dr. James Rothman, Nobel Laureate and Board Member at 1Cell.ai. “By integrating BioSkryb’s single-cell multi-omics chemistry with 1Cell.ai’s capabilities in single-cell isolation and multi-omic profiling, we are opening new frontiers in understanding cellular behavior and disease mechanisms at an unprecedented level of clarity.”
“This partnership with 1Cell.ai marks a significant advancement in single-cell research,” added Suresh Pisharody, CEO of BioSkryb Genomics. “By combining our innovative single-cell amplification and multi-omics chemistry with 1Cell.ai’s breakthrough CTC isolation, multi-omic profiling, and AI-powered analytics, we are providing researchers and clinicians with unprecedented tools to precisely understand disease at the molecular level.”
Our Vision for the Partnership
“Together, we will deliver transformative solutions that empower researchers and clinicians to tackle the most pressing challenges in biology, medicine, and drug discovery,” said Mohan Uttarwar, CEO and Co-founder of 1Cell.ai.
What’s Next
This partnership is a significant step in our mission to make precision oncology more accessible, actionable, and affordable for patients worldwide. By combining the power of BioSkryb’s world-class single-cell genomics with our AI-driven multi-omics platform, we are not just advancing cancer research; we are accelerating the path from data to life-saving therapy.
For partnership and collaboration enquiries, please contact us at [insert contact details].